Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrea Amico

Showing results (11-20 of 12) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 12 results.
Frontiers in Immunology|May 22, 2023
The shed P2X7 receptor is an index of adverse clinical outcome in COVID-19 patientsValentina Vultaggio-Poma, Juana Maria Sanz, Andrea Amico, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 2019
Clinical Assessment of 5-Fluorouracil/Leucovorin, Nab-Paclitaxel, and Irinotecan (FOLFIRABRAX) in Untreated Patients with Gastrointestinal Cancer Using <i>UGT1A1</i> Genotype-Guided DosingSmita S Joshi, Daniel V T Catenacci, Theodore G Karrison, et al.
Pageof 2

Showing results (11-20 of 12) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 12 results.
Frontiers in Immunology|May 22, 2023
The shed P2X7 receptor is an index of adverse clinical outcome in COVID-19 patientsValentina Vultaggio-Poma, Juana Maria Sanz, Andrea Amico, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 2019
Clinical Assessment of 5-Fluorouracil/Leucovorin, Nab-Paclitaxel, and Irinotecan (FOLFIRABRAX) in Untreated Patients with Gastrointestinal Cancer Using <i>UGT1A1</i> Genotype-Guided DosingSmita S Joshi, Daniel V T Catenacci, Theodore G Karrison, et al.
Pageof 2